Brain targeting of Atorvastatin loaded amphiphilic PLGA-b-PEG nanoparticles

References

• Aksungur P, Demirbilek M, Denkbas EB, Vandervoort J, Ludwig A, Unlu N. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies. J Control Release 2011; 151: 286–94
   PubMed Web of Science ®Google Scholar
• Ambruosi A, Yamamoto H, Kreuter J. Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats. J Drug Target 2005; 13: 535–42
   PubMed Web of Science ®Google Scholar
• Bourquin C, Wurzenberger C, Heidegger S, Fuchs S, Anz D, Weigel S, Sandholzer N, Winter G, Coester C, Endres S. Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response. J Immunother 2010; 33: 935–44
   PubMed Web of Science ®Google Scholar
• Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006; 6: 662–8
   PubMed Web of Science ®Google Scholar
• Cho EC, Glaus C, Chen J, Welch MJ, Xia Y. Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol Med 2010; 16: 561–73
   PubMed Web of Science ®Google Scholar
• Duncan R. Polymer therapeutics as nanomedicines: New perspectives. Curr Opin Biotechnol 2011; 22: 492–501
   PubMed Web of Science ®Google Scholar
• Eroglu H, Nemutlu E, Turkoglu OF, Nacar O, Bodur E, Sargon MF, Beskonakli E, Oner L. A quadruped study on chitosan microspheres containing atorvastatin calcium: Preparation, characterization, quantification and in-vivo application. Chem Pharm Bull (Tokyo) 2010; 58: 1161–7
   PubMed Web of Science ®Google Scholar
• Faucher L, Guay-Begin AA, Lagueux J, Côté MF, Petitclerc E, Fortin MA, Ultra-small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI. Contrast Media Mol Imaging, 2011; 6(4):209-18
   Google Scholar
• Gaspar VM, Sousa F, Queiroz JA, Correia IJ. Formulation of chitosan-TPP-pDNA nanocapsules for gene therapy applications. Nanotechnology 2011; 22(1)1–12
   Web of Science ®Google Scholar
• Gelperina S, Maksimenko O, Khalansky A, Vanchugova L, Shipulo E, Abbasova K, Berdiev R, Wohlfart S, Chepurnova N, Kreuter J. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters. Eur J Pharm Biopharm 2010; 74: 157–63
   PubMed Web of Science ®Google Scholar
• Greenspan P, Mayer EP, Fowler SD. Nile red: A selective fluorescent stain for intracellular lipid droplets. J Cell Biol 1985; 100: 965–73
   PubMed Web of Science ®Google Scholar
• Guo R, Zhang L, Qian H, Li R, Jiang X, Liu B. Multifunctional nanocarriers for cell imaging, drug delivery, and near-IR photothermal therapy. Langmuir 2010; 26: 5428–34
   PubMed Web of Science ®Google Scholar
• Hallaj-Nezhadi S, Lotfipour F, Dass C. Nanoparticle-mediated interleukin-12 cancer gene therapy. J Pharm Pharm Sci 2010; 13: 472–85
   PubMed Web of Science ®Google Scholar
• He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010; 31: 3657–66
   PubMed Web of Science ®Google Scholar
• Huynh NT, Roger E, Lautram N, Benoit JP, Passirani C. The rise and rise of stealth nanocarriers for cancer therapy: Passive versus active targeting. Nanomedicine (Lond) 2010; 5: 1415–33
   PubMed Web of Science ®Google Scholar
• Kayal S, Ramanujan RV. Anti-cancer drug loaded iron-gold core-shell nanoparticles (Fe@Au) for magnetic drug targeting. J Nanosci Nanotechnol 2010; 10: 5527–39
   PubMed Web of Science ®Google Scholar
• Kim JA, Aberg C, Salvati A, Dawson KA. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nanotechnol 2012; 7: 62–8
   Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65–81
   PubMed Web of Science ®Google Scholar
• Kreuter J, 2005. Application of nanoparticles for the delivery of drugs to the brain, The International Congress Series of Drug Transport(ers) and the Diseased Brain, S'Agaro(Girano), Spain, Vol. 1277, pp. 85–94
   Google Scholar
• Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003; 20: 409–16
   PubMed Web of Science ®Google Scholar
• Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J drug targeting 2002; 10: 317–25
   PubMed Web of Science ®Google Scholar
• Kuipers HF, van den Elsen PJ. Immunomodulation by statins: Inhibition of cholesterol vs. isoprenoid biosynthesis. Biomed Pharmacother 2007; 61: 400–7
   PubMed Web of Science ®Google Scholar
• Kumar S, Harrison N, Richards-Kortum R, Sokolov K. Plasmonic nanosensors for imaging intracellular biomarkers in live cells. Nano Lett 2007; 7: 1338–43
   PubMed Web of Science ®Google Scholar
• Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000; 31: 2442–9
   PubMed Web of Science ®Google Scholar
• Lu D, Goussev A, Chen J, Pannu P, Li Y, Mahmood A, Chopp M. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma 2004; 21: 21–32
   PubMed Web of Science ®Google Scholar
• McKeon-Fischer KD, Freeman JW. Characterization of electrospun poly(L-lactide) and gold nanoparticle composite scaffolds for skeletal muscle tissue engineering. J Tissue Eng Regen Med 2011; 5(7)560–8
   PubMedGoogle Scholar
• Musyanovych A, Dausend J, Dass M, Walther P, Mailander V, Landfester K. Criteria impacting the cellular uptake of nanoparticles: A study emphasizing polymer type and surfactant effects. Acta Biomater 2011; 7: 4160–8
   PubMed Web of Science ®Google Scholar
• Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007; 9: 257–88
   PubMed Web of Science ®Google Scholar
• Patterson AJ, Tang TY, Graves MJ, Müller KH, Gillard JH, In vivo carotid plaque MRI using quantitative T(2)* measurements with ultrasmall superparamagnetic iron oxide particles: A dose-response study to statin therapy. NMR Biomed, 2011;24(1):89–95
   Google Scholar
• Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2: 751–60
   PubMed Web of Science ®Google Scholar
• Ramge P, Unger RE, Oltrogge JB, Zenker D, Begley D, Kreuter J, von Briesen H. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur J Neurosci 2000; 12: 1931–40
   PubMed Web of Science ®Google Scholar
• Rosellini E, Barbani N, Giusti P, Ciardelli G, Cristallini C, Molecularly imprinted nanoparticles with recognition properties towards a laminin H-Tyr-Ile-Gly-Ser-Arg-OH sequence for tissue engineering applications. Biomed Mater, 2010;5(6):1–11
   Google Scholar
• Sandhu A, Handa H, Abe M. Synthesis and applications of magnetic nanoparticles for biorecognition and point of care medical diagnostics. Nanotechnology 2010; 21: 442001
   PubMedGoogle Scholar
• Schroeder U, Sommerfeld P, Sabel BA. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier. Peptides 1998; 19: 777–80
   PubMed Web of Science ®Google Scholar
• Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg 2004; 101: 104–7
   PubMed Web of Science ®Google Scholar
• Sparks DL, Connor DJ, Browne PJ, Lopez JE, Sabbagh MN. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging 2002; 6: 324–31
   PubMedGoogle Scholar
• Turkoglu OF, Eroglu H, Okutan O, Gurcan O, Bodur E, Sargon MF, Oner L, Beskonakli E. Atorvastatin efficiency after traumatic brain injury in rats. Surg Neurol 2009; 72: 146–52 (discussion 152)
   PubMedGoogle Scholar
• Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999; 30: 1969–73
   PubMed Web of Science ®Google Scholar
• Xie H, Zhu Y, Jiang W, Zhou Q, Yang H, Gu N, Zhang Y, Xu H, Xu H, Yang X. Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. Biomaterials 2011; 32: 495–502
   PubMed Web of Science ®Google Scholar
• Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78–84
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther 2008; 83: 761–9
   PubMed Web of Science ®Google Scholar